# Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma

> **NCT04061850** · — · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 88 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04061850
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-01
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-08-31
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04061850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04061850, "Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04061850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*